SR9009 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-09 and is reviewed periodically as new material appears.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
=== ACCC v. Valve Corporation === The Australian Competition & Consumer Commission (ACCC) announced it was taking action against Valve in 2014. On March 29, 2016, Valve was found guilty of breaching Australian consumer law because:
=== Catalase === The catalase test tests whether a microbe produces the enzyme catalase, which catalyzes the breakdown of hydrogen peroxide. Smearing a colony sample onto a glass slide and adding a solution of hydrogen peroxide (3% H2O2) will indicate whether the enzyme is present or not. Bubbling is a positive test while nothing happening is a negative result.
Shortly thereafter another new scandal broke out, known as the "CESID papers", which forced the resignation of the vice president of the Narcís Serra government and the Minister of Defense Julián García Vargas. Faced with the accumulation of scandals, the leader of CiU and president of the Generalitat de Catalunya, Jordi Pujol, withdrew the parliamentary support of the CiU deputies to the government, leaving the latter in a minority in the Cortes. The president of the government Felipe González had no choice but to call general elections for March 1996. The People's Party won the elections ─ it obtained 156 deputies, 15 more than the PSOE ─ and thus achieved its goal of ousting the Socialists from power, "after trying hard for more than a decade".
The common structure is composed of 130 amino acids with two beta sheets with five and six anti-parallel forming a roll structure. The monomer structure is composed of each monomer having one carbohydrate recognition domain, CRD, forming a beta-sandwich structure where the fold is then shared by all galectins. The dimerization, the non-covalent association of two identical monomers, is useful for the cross-linking glycoconjugates which is another crucial function of galectin-7 in linking sugars. This dimer arrangement is unique to just galectin-7 as it forms a dimer through back-to-back formation instead of side-to-side like other galectins. The carbohydrate binding site is highly conserved only recognizing beta galactosides forming a sequence of amino acids binding to the beta galactoside through hydrogen bonds. Some key residues formed from the CRD are histidine49, asparagine51, arginine53, asparagine62, tryptophan69, and glutamine72. Binding to oligosaccharides isn't required for the specific galectin-7 member to form homodimers because it still has preferential binding to the terminal or internal LacNAc carried by N-glycan as it still has multiple cellular functions from it being produced out of the LGALS7 gene. Galectin-7 binds to the beta galactoside, containing glycans, and interacts with cell-surface receptors and promotes nuclear functions. This protein can also modulate immune responses by suppressing T cell receptor signaling and influencing cell polarization.
As a concession made by Lamartine to popular aspirations, and in exchange for the maintaining of the tricolor flag, he conceded the Republican triptych of Liberté, Égalité, Fraternité, written on the flag, on which a red rosette was also to be added. The first collision took place as to the form which the 1848 Revolution was to take. Lamartine wished for them to maintain their original principles, with the whole country as supreme, whereas the revolutionaries under Ledru-Rollin wished for the Republic of Paris to hold a monopoly on political power. On 5 March the government, under the pressure of the Parisian clubs, decided in favor of an immediate reference to the people, and direct universal suffrage, and adjourned it until 26 April. This added the uneducated masses to the electorate and led to the election of the Constituent Assembly on 4 May 1848. The provisional government having resigned, the republican and anti-socialist majority on 9 May entrusted the supreme power to an Executive Commission consisting of five members: Arago, Pierre Marie de Saint-Georges, Garnier-Pagès, Lamartine, and Ledru-Rollin. The result of the general election, the return of a predominantly moderate, if not monarchical, constituent assembly dashed the hopes of those who had looked for the establishment, by a peaceful revolution, of their ideal socialist state. but they were not prepared to yield without a struggle, and in Paris itself they commanded a formidable force.
Sources: en.wikipedia.org
Baroness Louise Casey's report into the standards and culture of the Metropolitan Police is published, and describes critical failings, such as discrimination, the organisation's inability to police itself, failings towards women and children, and the loss of public confidence in the service. 22 March Data released for February shows that inflation increased from 10.1% to 10.4%, largely due to an increase in the cost of fresh food (particularly vegetables), non-alcoholic drinks, restaurant meals, and women's clothes. A major incident is declared, with 35 injuries reported, after the 76m-long RV Petrel research vessel tips over at a dock in Leith. Boris Johnson gives evidence to the cross-party Privileges Committee, relating to his conduct during Partygate. He insists that he "did not lie" to the House of Commons and always made statements in good faith. MPs back Rishi Sunak's new Brexit deal for Northern Ireland by 515 votes to 29. Scotland's First Minister, Nicola Sturgeon, issues a "sincere, heartfelt and unreserved" apology to people affected by the practice of forced adoption in Scotland during the 1950s, 1960s and 1970s. The RMT call off two strikes planned by staff at 14 train operators that were scheduled for 30 March and 1 April following discussions with the Rail Delivery Group. Prime Minister Rishi Sunak publishes details of his tax returns following calls for him to be more transparent about his finances. 23 March The Bank of England raises its key interest rate for the 11th consecutive time, from 4% to 4.25%, in response to the unexpected growth of inflation.
=== Digestion into peptide fragments === Peptides longer than about 50–70 amino acids long cannot be sequenced reliably by the Edman degradation. Because of this, long protein chains need to be broken up into small fragments that can then be sequenced individually. Digestion is done either by endopeptidases such as trypsin or pepsin or by chemical reagents such as cyanogen bromide. Different enzymes give different cleavage patterns, and the overlap between fragments can be used to construct an overall sequence.
== History == Protease inhibitory activity in blood plasma was first reported in the late 1800s, but it was not until the 1950s that the serpins antithrombin and alpha 1-antitrypsin were isolated, with the subsequent recognition of their close family homology in 1979. That they belonged to a new protein family became apparent on their further alignment with the non-inhibitory egg-white protein ovalbumin, to give what was initially called the alpha1-antitrypsin-antithrombin III-ovalbumin superfamily of serine proteinase inhibitors, but was subsequently succinctly renamed as the Serpins. The initial characterisation of the new family centred on alpha1-antitrypsin, a serpin present in high concentration in blood plasma, the common genetic disorder of which was shown to cause a predisposition to the lung disease emphysema and to liver cirrhosis. The identification of the S and Z mutations responsible for the genetic deficiency and the subsequent sequence alignments of alpha1-antitrypsin and antithrombin in 1982 led to the recognition of the close homologies of the active sites of the two proteins, centred on a methionine in alpha1-antitrypsin as an inhibitor of tissue elastase and on arginine in antithrombin as an inhibitor of thrombin. The critical role of the active centre residue in determining the specificity of inhibition of serpins was unequivocally confirmed by the finding that a natural mutation of the active centre methionine in alpha1-antitrypsin to an arginine, as in antithrombin, resulted in a severe bleeding disorder.
Xylazine is the most widely anesthetic agent used for short-duration operations in non-human animals. It does not have a medical use in humans. Pharmacokinetics of xylazine may be influenced by anesthesia since after an intravenous therapy about 1.1 mg/kg, the half-life of xylazine will increase to 118 minutes and the clearance will decrease to 6 mL/kg/min. Based on a recent study, if injecting the morphine, which is 0.1 or 0.2 mg/kg, in the vein at the same time can extend the terminal half-life to about 150 minutes and the clearance will not be influenced.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.